公司資料
Anebulo Pharmaceuticals 股價、新聞與催化劑
- 股票代碼:
- ANEB
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
0.33 USD (-5.69%)
收盤價
最後更新: 2026年8月21日
—
市值
股價為何變動
Current closing-price context is not available for ANEB.
公司概覽
Cannabis-Toxicity Antidote
Anebulo Pharmaceuticals develops a specific treatment for acute cannabis-induced toxicity in adults and children. The company’s approach directly blocks the cannabinoid receptor responsible for many central effects of THC.
Selonabant
Selonabant, or ANEB-001, is a small-molecule CB1 receptor antagonist. Oral selonabant blocked or reversed key THC effects in a controlled Phase 2 proof-of-concept study in healthy adults.
Pediatric Intravenous Strategy
Anebulo is prioritizing an intravenous formulation for pediatric cannabis poisoning rather than moving the adult oral product directly into Phase 3. The company has scaled the IV formulation and initiated a Phase 1 single-ascending-dose safety study.
未來催化劑
- Anebulo's story is now centered on selonabant and the company's decision to step away from Nasdaq. That makes the next chapter feel more like a value-maximization exercise around a finished Phase 2 asset than a broad public-development story.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。